Trinity Biotech plc (NASDAQ:TRIB) Sees Significant Decline in Short Interest

Trinity Biotech plc (NASDAQ:TRIB) saw a significant drop in short interest in January. As of January 15th, there was short interest totalling 29,100 shares, a drop of 50.3% from the December 31st total of 58,500 shares. Based on an average daily trading volume, of 207,300 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the shares of the stock are short sold.

Trinity Biotech Stock Down 2.9 %

NASDAQ:TRIB traded down $0.04 during midday trading on Wednesday, hitting $1.32. The company had a trading volume of 3,922,935 shares, compared to its average volume of 6,915,433. The company has a market capitalization of $5.89 million, a PE ratio of -0.58 and a beta of 1.01. Trinity Biotech has a 52-week low of $0.74 and a 52-week high of $3.55. The stock’s fifty day moving average price is $0.93 and its 200-day moving average price is $1.61.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Trinity Biotech in a research note on Wednesday. They issued a “hold” rating on the stock.

Institutional Trading of Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its holdings in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent SEC filing. Institutional investors own 78.97% of the company’s stock.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.